Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
KROS(NASDAQ:KROS) LEXINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences:
ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment
KROSAUSTIN, Texas, Aug. 21, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "we"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today released...
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
KROSLEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced the U.S. Food and Drug Administration (“FDA”) granted Orphan Drug designation for KER-065 for the treatment of Duchenne muscular dystrophy (“DMD”).
Kratos Launches New Website, Debuts Tagline: “Readiness Delivered”
KROSNew digital experience underscores Kratos’ mission to rapidly deliver affordable, disruptive defense hardware, software and technologies
New digital experience underscores Kratos’ mission to rapidly deliver affordable, disruptive defense hardware, software and technologies
Keros Therapeutics Reports Second Quarter 2025 Financial Results
KROSLEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today reported financial results for the quarter ended June 30, 2025.
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst
KROSBofA's Zemansky downgraded Keros to Neutral, citing limited near-term upside, cautious sentiment, and unresolved investor concerns.
B of A Securities Downgrades Keros Therapeutics to Neutral, Lowers Price Target to $18
KROSKeros Therapeutics Board Determines To Initiate Process To Return $375M Of Excess Capital To Stockholders
KROSWedbush Reiterates Neutral on Keros Therapeutics, Maintains $15 Price Target
KROSKeros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
KROSKeros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% of workforce amid review.
Keros Discontinues Cibotercept Development In PAH After TROPOS Trial Safety And Efficacy Analysis
KROSKeros Therapeutics To Cut Workforce By 45% Following Cibotercept Discontinuation, Expects $17M Annual Savings
KROSKeros Therapeutics Reports Topline Data From TROPOS Trial, Phase 2 Clinical Trial Of Cibotercept In Combination With Background Therapy In PAH Patients
KROSScotiabank Maintains Sector Outperform on Keros Therapeutics, Lowers Price Target to $26
KROSKeros' Largest Stockholder, ADAR1, Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth At The Upcoming Keros Annual Meeting Of Stockholders On June 4, 2025
KROSHC Wainwright & Co. Maintains Buy on Keros Therapeutics, Lowers Price Target to $25
KROSKeros Therapeutics Q1 EPS $3.62, Sales $211.25M
KROSKeros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan
KROSKeros Therapeutics launches strategic review and adopts rights plan after investor activity signals potential changes in company control.
Keros Therapeutics Initiates Formal Review Of Strategic Alternatives To Maximize Stockholder Value
KROSTruist Securities Maintains Buy on Keros Therapeutics, Lowers Price Target to $25
KROSWedbush Reiterates Neutral on Keros Therapeutics, Maintains $15 Price Target
KROSForecasting The Future: 7 Analyst Projections For Keros Therapeutics
KROSHC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $40 Price Target
KROSKeros Reports Early Data from Phase 1 Trial of Muscle Disorder Drug
KROSAnalyst Expectations For Keros Therapeutics's Future
KROSHC Wainwright & Co. Maintains Buy on Keros Therapeutics, Lowers Price Target to $40
KROSKeros Therapeutics Q4 EPS $(1.14) Misses $(0.96) Estimate, Sales $3.04M Miss $15.42M Estimate
KROSKeros Therapeutics Announces Additional Update On The Phase 2 TROPOS Trial: Company Says It Voluntarily Halted All Dosing In The TROPOS Trial Based On The Ongoing Safety Review Due To New Observations Of Pericardial Effusion Adverse Events
KROSTruist Securities Maintains Buy on Keros Therapeutics, Lowers Price Target to $43
KROSKeros Therapeutics To Present Three Abstracts At ASH Annual Meeting
KROSKeros Therapeutics Presents Additional Clinical Data From Its KER-012 Program And Preclinical Data From Its KER-050 Program At The American Society Of Bone And Mineral Research 2022 Annual Meeting
KROS